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Proteus mirabilisNO-051/03, representative of a multidrug-resistant clone expressing the CMY-16 AmpC-type -lactamase and
circulating in Europe since 2003, was sequenced by aMiSeq platform using a paired-end approach. The genome was assembled
in 100 scaffolds with a total length of 4,197,318 bp. Analysis of the draft genome sequence revealed the presence of several ac-
quired resistance determinants to -lactams, aminoglycosides, phenicols, tetracyclines, trimethoprim, and sulfonamides, of one
plasmid replicon, and of a type I-E clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (Cas)
adaptive immune system.
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Proteus mirabilis is one of the leading causes of urinary tractinfections, especially in patients with functional or structural
abnormalities of the urinary tract or with indwelling catheters, but
it can also cause infections of other sites and bacteremia (1). In this
species, which lacks functional chromosomal -lactamase genes,
acquired -lactamase genes play an important role in the evolu-
tion of antibiotic resistance (2).
P. mirabilis NO-051/03 (also referred as IT NO-051/03) (3)
was isolated in 2003 from a skin and soft tissue infection sample
from a hospitalized patient from northern Italy (Novara) (4). The
strain was resistant to penicillins and expanded-spectrum cepha-
losporins, due to the production of an acquired AmpC-type
-lactamase (ACBL) of the CMY lineage, named CMY-16 (3–5),
and also to fluoroquinolones. The strain, which caused a clonal
outbreak in northern Italy, was subsequently found to be highly
related to a clone spreading in Europe and North Africa since the
1990s (3).
Bacterial DNA was subjected to whole-genome sequencing
with a MiSeq platform (Illumina, Inc., San Diego, CA), using a 2
250-bp paired-end approach. In total, 2,216,404 reads were ob-
tained and assembled using ABySS (6) into 100 scaffolds (208 bp
in size), with a total length of 4,197,318 bp and an N50 of
160,469 bp. The genome raw coverage was 130. The average
GC content was 39%.
A total of 3,778 coding sequences (CDSs), 82 tRNAs, 48
rRNAs, and 2 clustered regularly interspaced short palindromic
repeat (CRISPR) systems were annotated by PGAP (http://www
.ncbi.nlm.nih.gov/genome/annotation_prok). Further analysis
showed the presence of a type I-E CRISPR-associated protein
(Cas) adaptive immune system characterized by 20 spacers, of
which 16 lacked any detectable identity with sequences in nucle-
otide databases, while 3 matched prophage sequences, and one
matched a DNA fragment present between the mucB and resD
genes in several conjugative IncL/M-type plasmids. These data
suggest the ability of NO-051/03 to resist invasion by a number of
phages and IncL/M-type plasmids.
The antimicrobial resistome of NO-051/03 was investigated
with ResFinder (7), which confirmed the presence of two acquired
-lactamase genes (blaCMY-16 and blaTEM-1b) and detected addi-
tional acquired resistance genes to aminoglycosides (strAB, aacA4,
aac(3)-I, aadA1, and aph(3=)-Ic), aminoglycosides and quino-
lones (aac(6=)Ib-cr), chloramphenicol (cat and catA1), tetracy-
clines (tet(A)), trimethoprim (dfrA1), and sulfonamides (sul1 and
sul2). Further analysis of the quinolone resistance-determining
regions of topoisomerase genes (8) showed the presence of muta-
tions previously linked to reduced susceptibility to fluoroquino-
lones, namely, those encoding S83R in GyrA, S464Y in GyrB, and
S80R in ParC.
PlasmidFinder (9) detected the presence of an IncQ1 replicon,
while PHAST (10) revealed the presence of 5 intact, 2 incomplete,
and 2 putative prophages.
To the best of our knowledge, this is the first genome sequenc-
ing project of a P.mirabilis isolate producing an ACBL. The results
from this project are expected to broaden the knowledge on the
genetic factors that have contributed to the successful interna-
tional spread of such isolates.
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Nucleotide sequence accession numbers. The complete ge-
nome sequence of P.mirabilis NO-051/03 was deposited at DDBJ/
EMBL/GenBank databases under the accession number
LGAY00000000. The version described in this paper is the first
version, LGAY01000000.
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